| 000 | 01713nam a22003737a 4500 | ||
|---|---|---|---|
| 008 | 221213s20222022 xxu||||| |||| 00| 0 eng d | ||
| 022 | _a2168-8184 | ||
| 024 | _a10.7759/cureus.30106 [doi] | ||
| 024 | _aPMC9643074 [pmc] | ||
| 040 | _aOvid MEDLINE(R) | ||
| 099 | _a36381906 | ||
| 245 | _aA Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis. | ||
| 251 | _aCureus. 14(10):e30106, 2022 Oct. | ||
| 252 | _aCureus. 14(10):e30106, 2022 Oct. | ||
| 253 | _aCureus | ||
| 260 | _c2022 | ||
| 260 | _fFY2023 | ||
| 260 | _p2022 Oct | ||
| 265 | _sepublish | ||
| 266 | _d2022-12-13 | ||
| 520 | _aWhile rare, serious adverse effects including euglycemic diabetic ketoacidosis (EDKA) have been associated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) use. We present an interesting case of SGLT2i-induced EDKA occurring two years after initiation of therapy. Most patients with EDKA recover with prompt recognition and treatment. Patient education about identifying early signs remains a cornerstone of early identification and response to SGLT2i-induced EDKA. Copyright © 2022, Rao et al. | ||
| 546 | _aEnglish | ||
| 650 | _aIN PROCESS -- NOT YET INDEXED | ||
| 651 | _aMedStar Union Memorial Hospital | ||
| 656 | _aInternal Medicine | ||
| 656 | _aInternal Medicine Residency | ||
| 657 | _aCase Reports | ||
| 700 |
_aKumar, Kaushik _bMUMH _cInternal Medicine Residency _dMBBS _eResident PGY 2 |
||
| 700 |
_aRao, Shiavax _bMUMH _cInternal Medicine Residency _dMD _eResident PGY 3 |
||
| 700 |
_aSaleh, Nahar _bMUMH |
||
| 790 | _aKumar K, Rao SJ, Saleh N | ||
| 856 |
_uhttps://dx.doi.org/10.7759/cureus.30106 _zhttps://dx.doi.org/10.7759/cureus.30106 |
||
| 942 |
_cART _dArticle |
||
| 999 |
_c98 _d98 |
||